Acute hepatitis B is a significant viral infection caused by the hepatitis B virus (HBV), affecting the liver and potentially leading to severe liver damage. Monitoring specific serological markers and cytokines is crucial in assessing the immune response and disease progression in patients with acute hepatitis B Aim: This study aims to assess the levels of hepatitis B serological markers (HBsAg, anti-HBc, HBeAg, anti-HBe), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and procalcitonin (PCT) in patients with acute hepatitis B. Materials and methods: A cross-sectional study was conducted in Kirkuk city from June 1, 2023, to July 31, 2024, to evaluate the serological and molecular markers in patients with acute hepatitis B infection. The study included 44 patients aged 20-75 years who were admitted to Hepatology and Gastroenterology centers in Kirkuk. An equal number of healthy controls were selected, matched for age and sex, and were recruited from blood donors. Blood samples were collected from each participant for serological testing of IL-6, TNF-α, IFN-γ, and PCT using ELISA, and for biochemical tests including ALT, AST, ALP, and TSB. Additionally, HBV DNA was isolated using the ZR Viral DNA Kit and quantified using real-time PCR. Results: The study showed a significant prevalence of HBsAg and HBcIgM among all patients, confirming acute HBV infection. The study found that HBeAg-positive patients had significantly higher viral loads compared to HBeAg-negative patients. Biochemical parameters such as ALT, AST, ALP, and TSB were significantly elevated in patients compared to controls, indicating liver inflammation and damage. Inflammatory markers IL-6, TNF-α, and IFN-γ were also significantly higher in patients, highlighting the systemic inflammatory response to acute HBV infection. The study concluded that acute hepatitis B is associated with significant biochemical and inflammatory disturbances, with higher viral loads correlating positively with ALT, TSB, and IL-6 levels. These findings underscore the importance of comprehensive monitoring of viral load and inflammatory markers in the management of acute hepatitis B to improve patient outcomes
Acute hepatitis is a term used to describe a wide variety of conditions characterized by acute inflammation of the hepatic parenchyma or injury to hepatocytes resulting in elevated liver function indices. In general, hepatitis is classified as acute or chronic based on the duration of the inflammation and insult to the hepatic parenchyma. If the period of inflammation or hepatocellular injury lasts for less than six months, characterized by normalization of the liver function tests, it is called acute hepatitis. In contrast, if the inflammation or hepatocellular injury persists beyond six months, it is termed chronic hepatitis (1). The most common infectious cause of acute hepatitis is due to a viral infection (acute viral hepatitis). Nevertheless, acute hepatitis can result from a wide variety of noninfectious causes as well that include but not limited to are drugs (drug-induced hepatitis), alcohol (alcoholic hepatitis), immunologic (autoimmune hepatitis, primary biliary cholangitis) or as a result of indirect insult secondary to biliary tract dysfunction (cholestatic hepatitis), pregnancy-related liver dysfunction, shock or metastatic disease (2,3). Acute hepatitis B infection has an incubation period of 1-6 months. The disease predominantly manifests as anicteric hepatitis, where the majority of patients remain asymptomatic. However, those with anicteric hepatitis are at a higher risk of progressing to chronic hepatitis. Symptomatic patients exhibit similar clinical features as those with icteric hepatitis. Viral hepatitis is a general term describing liver infection caused by viruses actively replicating in the liver (4). Like hepatitis caused by other agents, such as alcohol and drug abuse or metabolic disorders, a typical feature of the disease is jaundice (5). Acute hepatitis is a transient episode of inflammatory liver disease. During this phase of up to six months, the disease may be clinically unapparent, or accompanied by clinical features ranging from mild symptoms such as jaundice, nausea and malaise to severe symptoms such as liver failure or death. Chronic hepatitis, in which markers of the disease can be found for a period longer than six months, has the same range of clinical outcomes seen in acute hepatitis (1). Icteric hepatitis is often preceded by a prodromal period characterized by a serum sickness-like syndrome. The symptoms during this phase are more constitutional and include anorexia, nausea, vomiting, low-grade fever, myalgia, fatigue, altered taste and smell sensations (including aversion to food and cigarettes), and intermittent mild to moderate pain in the right upper quadrant and epigastric region. In severe cases, patients may develop fulminant or subfulminant hepatitis, presenting with more serious complications such as hepatic encephalopathy, somnolence, disturbances in sleep patterns, mental confusion, coma, ascites, gastrointestinal bleeding, and coagulopathy. Understanding these varied clinical presentations is crucial for timely diagnosis and effective management of acute hepatitis B infection (6,7). Diagnosis of chronic hepatitis B have evolved from the simple detection of HBsAg through the complex antibody response against individual viral proteins and to the detection and quantification of viral DNA. Implementation of increasingly sensitive methods of HBV DNA quantification has greatly aided the diagnosis and management of disease (8). Viral load measurement plays a significant role during therapy, as most guidelines propose that suppression of HBV replication is a major therapeutic goal (9). Cytokines have a crucial part in the pathogenesis, persistence of infection, and prognosis of hepatitis B virus (HBV) infection as HBV does not cause direct liver destruction; rather, disease-related complications and prognosis are more associated with immune system action, specifically cytokines such as TNF-α, IFN-γ, IL-6, IL-10, and other cytokines. Acute phase reactants (APR) are inflammation markers that exhibit significant changes in serum concentration during inflammation (10). These are also important mediators produced in the liver during acute and chronic inflammatory states. Interleukin-6 (IL-6) is the primary cytokine responsible for inducing the production in the liver. IL-1, tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) can also induce the production of acute-phase reactants. Acute phase reactants cause several adverse effects (11). These include fever, anemia of chronic disease, anorexia, somnolence, lethargy, amyloidosis, and cachexia (fat and muscle loss, anorexia, weakness). (12,13). This study aims to assess the levels of hepatitis B serological markers (HBsAg, anti-HBc, HBeAg, anti-HBe), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), and procalcitonin (PCT) in patients with acute hepatitis B.
A cross-sectional study was carried out in Kirkuk city from 1st June 2023 to the end of July 2024. The number of hepatitis patients understudy were 44 patienst with acute hepatitis B infection whose ages were between 20-75 years old. These patients admitted to Hepatology and Gastroenterology centers of Kirkuk. An interview was carried out with these patients using questionnaire form designed by the investigator and consisted of the following variables. age, sex, occupation. The control group who was matched to the patients, included 44 individuals who were apparently haven’t any diseases who admitted to blood bank for blood donation.
Five ml of blood was collected by vein puncture using 5 ml syringe from each patient enrolled in this study. Blood samples were placed into two tubes, one of them containing anticoagulant EDTA. The second part of the sample was 3 ml which placed in plane tubes, left for 30 minutes at 37 °C for clotting and centrifuged at 3000 rpm for 15 minutes, the obtained plasma from the first tube was aspirated using automatic micropipette and transferred to Eppendorf tubes and stored in deep freeze at -20°C for late molecular test of HBV viral load and sera from the 2nd tube were then aspirated and transferred into Eppendorf tubes which then stored in deep freeze at -20°C for late serological testing for IL-6, TNF-α, IFN-γ, and PCT tests using ELISA technique and biochemical tests for assessment of ALT, AST, ALP, TSB.
Isolation of HBV-DNA
(ZR Viral DNA Kit, Zymo Research Corp. USA)
The ZR Viral DNA Kit™ allows for the rapid isolation of high-quality viral DNA from various biological sources. The kit uses a unique buffer and Zymo-Spin™ IC column to denature viral particles and recover DNA. The DNA can be eluted with water or the supplied elution buffer and is suitable for PCR and other downstream applications.
Buffer Preparation: Add 24 ml of 100% ethanol to the 6 ml DNA wash buffer concentrate to obtain the final DNA wash buffer solution.
Procedure
In a 1.5 ml microcentrifuge tube, add 4 volumes of ZR viral DNA buffer to each volume of sample (e.g., 800 μl ZR viral DNA buffer to 200 μl serum), mix briefly by vortexing, and let stand at room temperature for 5-10 minutes.
Transfer the mixture to a Zymo-Spin™ IC column in a collection tube, centrifuge for 1 minute, and discard the flow-through.
Add 300 μl of DNA wash buffer to the column, centrifuge for 1 minute, and discard the flow-through. Repeat this step.
Place the Zymo-Spin™ IC column into a microcentrifuge tube, add 6-10 μl of DNA elution buffer directly to the column matrix, let stand at room temperature for 1 minute, and centrifuge for 1 minute to elute the DNA.
Quantitative detection of HBV-DNA real-time PCR.
(HBV Real-TM Quant, Sacace Biotechnology, Italy).
HBV Real-TM Quant is a real-time test for the quantitative detection of Hepatitis B Virus in human plasma. The HBV DNA is extracted from plasma, amplified using real time amplification and detected using fluorescent reporter dye probes specific for HBV or HBV IC. Internal control (IC) serves as an amplification control for each individually processed specimen and to identify possible inhibition. The IC is detected in a channel other than the HBV DNA. Monitoring the fluorescence intensities during Real Time allows the detection of the accumulating product without having to reopen the reaction tube after the amplification.
Preparation: The total reaction volume was 25 μl, the volume of DNA sample was 12.5 μl.
1. One set of reagents was thawed, vortexed and the tubes centrifuged briefly.
2. Requested quantity of reaction tubes were prepared including 3 extraction controls, negative amplification control and 4 standards.
3. A new tube for N samples was prepared (including controls and standards) the reaction mixes as follow:
7.5 μl *N of PCR-mix-1-TM HBV.
5 μl *N of PCR-mix-2-FRT.
0.5 μl *N of Polymerase (TaqF), vortexed thoroughly and centrifuged briefly.
4. An amount of 12.5 μl of Reaction Mix was added into each tube.
5. An amount of 12.5 μl of extracted DNA sample was added to the appropriate tubes with reaction Mix.
6. Prepare for each run 4 standards:
- An amount of 12.5 μl of QS1 HBV was added into 2 tubes each labelled QS1 HBV and mixed by pipetting.
- An amount of 12.5 μl of QS2 HBV was added into 2 tubes each labelled QS2 HBV and mixed by pipetting.
7- The tubes were inserted in the thermalcycler and the instrument was programmed.
fluorescence was detected at the 3rd step of cycling 2 stage (60 °C) in FAM/Green and
JOE/Yellow/Hex/Cy3 fluorescence channels.
8- Internal control was detected on the FAM (Green) channel, HBV DNA was detected on the JOE (Yellow)/ HEX/Cy3 channel (Figure 3.5).
Statistical analysis
Computerized statistically analysis was performed using Minitab version 17 statistic program. Comparison was carried out using Chi-square (X2), T-Test probability and analysis of variance (ANOVA) and interpreted as follows:
P value> 0.01 : Highly Significant (HS).
0.1 ≤ (P value) ≤ 0.5 : Significant (S)
P value> 0.05 : Non-significant (NS).
Interpretation of R value (correlation coefficient)
–0.70. A strong negative correlation.
–0.50. A moderate negative correlation.
–0.30. A weak negative correlation.
+0.30. A weak positive correlation.
+0.50. A moderate positive correlation.
+0.70. A strong positive correlation.
Table 1 presents the demographic properties of 44 patients diagnosed with acute hepatitis B (AHB). The majority of the patients are male, accounting for 59.09% (26 individuals), while females make up 40.91% (18 individuals). The age distribution reveals that the largest age group is 30-39 years, representing 43.18% (19 patients), followed by the 20-29 years group at 31.82% (14 patients). Smaller proportions are seen in the 40-49 years group at 11.36% (5 patients) and the 50-59 years group at 13.64% (6 patients). Regarding residence, a higher percentage of patients reside in urban areas (59.09%, 26 patients) compared to rural areas (40.91%, 18 patients).
Table 1: Demographic properties of acute hepatitis B patients
Demographic properties of AHB patients (n:44) | No. | % | |
Sex | Male | 26 | 59.09% |
Female | 18 | 40.91% | |
Age groups (years) | 20-29 | 14 | 31.82% |
30-39 | 19 | 43.18% | |
40-49 | 5 | 11.36% | |
50-59 | 6 | 13.64% | |
Residence | rural | 18 | 40.91% |
Urban | 26 | 59.09% | |
Total | 44 | 100% | |
Table 2 outlines the serological markers for 44 patients with acute hepatitis B. All patients tested positive for HBsAg (100%), confirming active hepatitis B infection. The presence of HBeAg was evenly split, with 50% (22 patients) testing positive and 50% (22 patients) testing negative. A smaller proportion, 18.18% (8 patients), tested positive for HBeAb, while the majority, 81.82% (36 patients), were negative. For HBcIgG, 20.45% (9 patients) were positive, indicating previous exposure or chronic infection, while 79.55% (35 patients) were negative. Consistent with acute infection, all patients (100%) tested positive for HBcIgM. None of the patients had detectable HBsAb, with all 44 (100%) testing negative, indicating no immunity developed yet. This serological profile is characteristic of acute hepatitis B infection, with universal positivity for HBsAg and HBcIgM, and varying presence of other markers.
Table 2: Hepatitis B Serological Markers in Acute Hepatitis B Patients
Hepatitis B Serological Markers | No. | % | |
HBs/Ag | Positive | 44 | 100% |
Negative | 0 | 0% | |
Hbe/Ag | Positive | 22 | 50% |
Negative | 22 | 50% | |
Hbe/Ab | Positive | 8 | 18.18% |
Negative | 36 | 81.82% | |
HBc/IgG | Positive | 9 | 20.45% |
Negative | 35 | 79.55% | |
HBc/IgM | Positive | 44 | 100% |
Negative | 0 | 0% | |
HBs/Ab | Positive | 0 | 0% |
Negative | 44 | 100% | |
Total | 44 | 100% | |
The comparison of biochemical parameters between acute hepatitis B patients and a control group reveals significant differences, as shown in the table. ALT and AST levels are markedly higher in hepatitis B patients (157.45 ± 69.66 IU/L and 39.50 ± 16.92 IU/L, respectively) compared to controls (30.1 ± 10.1 IU/L and 20.4 ± 8.34 IU/L), indicating liver inflammation and damage. ALP and TSB levels are also elevated in patients (136.77 ± 85.46 IU/L and 3.17 ± 1.97 mg/dl) versus controls (70.54 ± 15.1 IU/L and 1.17 ± 0.51 mg/dl), reflecting cholestasis and bilirubin metabolism disruption. Inflammatory markers such as IL-6, TNF-α, and IFN-γ are significantly higher in patients (186.15 ± 52.37 pg/ml, 64.65 ± 11.44 pg/ml, and 225.78 ± 39.82 pg/ml) compared to controls (50.19 ± 11.31 pg/ml, 20.16 ± 5.17 pg/ml, and 88.17 ± 13.1 pg/ml), highlighting systemic inflammation. Additionally, PCT levels are elevated in patients (11.86 ± 4.57 pg/ml) versus controls (1.17 ± 0.59 pg/ml), indicating severe infection or inflammation. All differences are statistically significant (P < 0.001), underscoring the profound biochemical disturbances associated with acute hepatitis B.
Table 3: The comparison of biochemical parameters between acute hepatitis B patients and a control group
Parameter | Acute Hepatitis B (n=44) | Control Group (n=44) | P-value
|
Mean ± SD | Mean ± SD | ||
ALT (IU/L) | 157.45 ± 69.66 | 30.1 ± 10.1 | <0.001 |
AST (IU/L) | 39.50 ± 16.92 | 20.4 ± 8.34 | <0.001 |
ALP (IU/L) | 136.77 ± 85.46 | 70.54 ± 15.1 | <0.001 |
TSB (mg/dl) | 3.17 ± 1.97 | 1.17 ± 0.51 | <0.001 |
IL-6 (pg/ml) | 186.15 ± 52.37 | 50.19± 11.31 | <0.001 |
TNF-α (pg/ml) | 64.65 ± 11.44 | 20.16± 5.17 | <0.001 |
IFN-γ (pg/ml) | 225.78 ± 39.82 | 88.17 ± 13.1 | <0.001 |
PCT (pg/ml) | 11.86 ± 4.57 | 1.17 ± 0.59 | <0.001 |
Table 4 presents the comparison of viral load (in copy/ml x106) among different hepatitis B serological marker statuses in patients. The data shows that patients who are HBeAg positive have a significantly higher mean viral load (2.52 ± 0.67) compared to HBeAg negative patients (1.79 ± 0.71), with a P-value of 0.001, indicating a strong association between HBeAg positivity and higher viral replication. Conversely, the presence of HBeAb does not significantly impact the viral load, with mean values of 1.98 ± 0.70 for HBeAb negative and 2.09 ± 0.80 for HBeAb positive patients, and a P-value of 0.87, suggesting no significant difference. Additionally, HBcIgG positive patients exhibit a significantly higher viral load (2.77 ± 0.80) compared to HBcIgG negative patients (1.89 ± 0.70), with a P-value of 0.001, indicating that HBcIgG positivity is also associated with higher viral replication.
Table 4: Comparison of viral load level among different hepatitis B serological marker statuses in patients
Hepatitis B Serological Markers | viral load copy/ml (x106) | P-value | ||
Mean | SD | |||
Hbe/Ag | Negative | 1.79 | 0.71 | 0.001 |
Positive | 2.52 | 0.67 | ||
Hbe/Ab | Negative | 1.98 | 0.70 | 0.87 |
Positive | 2.09 | 0.80 | ||
HBc/IgG | Negative | 1.89 | 0.70 | 0.001 |
Positive | 2.77 | 0.80 | ||
The correlation analysis reveals significant relationships between viral load and several biochemical and inflammatory markers in patients with acute hepatitis B. There is a strong positive correlation between viral load and ALT (r = 0.453, P = 0.001) and TSB (r = 0.454, P = 0.001), indicating that higher viral loads are associated with increased liver enzyme levels and total serum bilirubin, markers of liver inflammation and damage. Additionally, IL-6 (r = 0.518, P = 0.001) shows a significant positive correlation with viral load, suggesting a link between higher viral replication and systemic inflammation. IFN-γ also correlates positively with viral load (r = 0.325, P = 0.016), indicating an immune response to higher viral levels. Although PCT shows a significant positive correlation with viral load (r = 0.272, P = 0.037), its relationship is weaker compared to other markers. AST, ALP, and TNF-α did not show significant correlations with viral load, as indicated by their P-values (0.331, 0.470, and 0.205, respectively). These findings highlight the complex interplay between viral replication and host responses in acute hepatitis B.
Table 5: The correlation analysis between viral load and several biochemical and inflammatory markers in patients with acute hepatitis B
Parameter | Viral Load (X106) | |
r value | P-value | |
ALT | 0.453 | 0.001 |
AST | 0.068 | 0.331 |
ALP | 0.012 | 0.470 |
TSB | 0.454 | 0.001 |
IL-6 | 0.518 | 0.001 |
TNF-α | 0.128 | 0.205 |
IFN-γ | 0.325 | 0.016 |
PCT | 0.272 | 0.037 |
The demographic analysis of the 44 patients with acute hepatitis B (AHB) reveals a higher prevalence in males (59.09%) compared to females (40.91%). This gender distribution aligns with other studies that report a male predominance in hepatitis B infections, potentially due to higher exposure risks in men. The age distribution shows the largest group of patients is within the 30-39 years age range (43.18%), followed by the 20-29 years group (31.82%). These findings are consistent with studies indicating that younger adults are more likely to contract hepatitis B, often due to lifestyle factors and occupational exposures. A study done by Jasim (14) in Karbala, showed highest rate of infection was recorded in patients within the age group 41-60. Mustapha et al (15) showed that 41.6% of HBV patients were in age group 40-49 years. The association between chronic hepatitis B and age over 41 years can be explained by the increased chance of HBV infection that results from a longer lifespan and life time exposure to unprotected sex and mother-to-child transmission. Serological marker analysis indicates that all patients tested positive for HBsAg and HBcIgM, confirming acute hepatitis B infection. The presence of HBeAg in 50% of patients suggests active viral replication in a significant portion of the cohort. This is supported by studies showing that HBeAg positivity is a marker of active HBV replication and increased infectivity. Additionally, 18.18% of patients tested positive for HBeAb, which typically appears as the immune system begins to control viral replication, potentially indicating a transition towards resolving the infection. The absence of HBsAb in all patients confirms the acute nature of the infection, as these antibodies usually develop during the convalescent phase or after vaccination.
Hepatitis B surface antigen and HBeAg can be immense contribution in the management of patients since HBcAg described infectivity status of the patient as well as the persistence of the chronic HBV infection, HBeAg subject may be expected of developing persistence liver disease leading to cirrhosis and even primary liver cancer if not treated (12). It is estimated that about 5% of immunocompetent adult patients with genuine acute hepatitis B progress to chronic infection (66). Among patients with chronic HBV infection, the rate of clearance of HBsAg is approximately 0.5 to 1% per year, disappearance of HBsAg is frequent, but not always followed by the appearance of anti-HBs (1,2). The result indicated early stage of acute hepatitis B infection and active replication or may be mutant strains of HBV exist that replicate without producing HBeAg (12). Hama et al (16) and Al-Jaaf (17) demonstrated that high rates of HBsAg were recorded in patients with chronic hepatitis B. Youssif (18) found a high rate of HBeAg (54.2%) and low rate of anti-HBe (44.58%) in patients with chronic active hepatitis. The present study revealed that all patients with acute hepatitis B had anti-HBc IgM (100%), while only 10.7% of those with chronic hepatitis had anti-HBc-IgM. Dolan et al (19) reported that anti-HBc IgM is a marker of activity of disease which is usually increased in acute phase. Shin et al (20) found that anti- HBc IgM was found in 79.4% of patients with acute hepatitis B. During acute infection, anti-HBc is predominantly class IgM, which is an important marker of HBV infection during the window period between the disappearance of HBsAg and the appearance of anti-HBs. Anti-HBc IgM may remain detectable for up to two years after acute infection. Furthermore, the titre of anti-HBc IgM may increase to detectable levels during exacerbations of chronic hepatitis B (21,22). Report of US / CDC in 2017 confirmed that anti-HBc antibody is developed in all HBV infections, as it is appeared shortly after HBsAg in the acute disease, indicating HBV infection at some undefined time in the past (23). Furthermore, anti-HBc antibody is present even in window period when the HBsAg has disappeared and yet anti- HBs-Ab is not detectable (24). Hepatitis B surface antigen and anti-HBe had been used to know infectivity and viral replication, but their use for this purpose has mostly been replaced by HBV DNA assay (25). However, active viral replication is sustained in some patients with HBeAg seroconversion due to mutations in the core / pre-core region that inhibit or decrease the production of HBeAg (26,27). However, HBeAg seroconversion may be delayed for years to decades in patients with chronic HBV infection (28,29). The presence of HBeAg is usually associate with high levels of HBV DNA in serum and active liver disease and is associate with higher rates of transmission of HBV infection. However, HBeAg positive patients with perinatal acquired HBV infection may have normal serum ALT concentration and minimal inflammation in the liver (17). The biochemical parameter comparison between AHB patients and the control group reveals significant elevations in ALT, AST, ALP, and TSB levels among patients, indicating liver inflammation and damage. Elevated ALT and AST levels are hallmark indicators of hepatocellular injury, commonly seen in acute viral hepatitis. Similarly, increased ALP and TSB levels reflect cholestasis and impaired bilirubin metabolism, further highlighting hepatic dysfunction in AHB patients. Level of ALT is an important factor to initiate the treatment of chronic hepatitis B infection because the elevated ALT levels indicate immune-mediated inflammation to eliminate HBV-infected hepatocytes and a higher rate of HBeAg seroconversion (12). In patients who recover, normalization of serum aminotransferases usually occurs within one to four months. Persistent elevation of serum ALT for more than six months indicates progression to chronic hepatitis (13). Inflammatory markers such as IL-6, TNF-α, and IFN-γ were significantly higher in AHB patients compared to controls, underscoring the systemic inflammatory response to acute HBV infection. Elevated IL-6 levels are indicative of acute-phase inflammation, while increased TNF-α and IFN-γ levels reflect the body's immune response to viral infection. The significant elevation of PCT in AHB patients suggests a severe inflammatory response, which is corroborated by other studies linking high PCT levels with severe infections. Immediately following the viral infection, a strong host response has been initiated, this includes activation of preexisting antiviral defense machinery commitment to apoptosis, and production of specific cytokines, these events lead to the reduction of the viral replication and to the limitation of viral spread (27,28). Beside that, the interaction of the viral proteins with the cellular proteins starts a cellular reaction that may lead to release the first wave of cytokines, virus induce expression of cytokines is primarily due to stimulation of one or more of signal transduction cascades, leading to activation of specific transcription factors, then release of cytokines which regulate and modulate the host immune response (12,13). Cytokines act as a key role in regulation of the immune response to hepatitis B virus infection, both directly, through inhibition of viral replication or indirectly through determination of predominant pattern of the host response (29). Interleukin -8 is important cytokine associated with liver damage. It is a chemotatic factor of neutrophils and T- cells and play a role in hepatic injury in patients with chronic hepatitis B –remarkable increase of IL-8 leads to accumulation of CD8 which get direct and immediate access to the target hepatocyte and the resident intrahepatic macrophages, subsequently causing damage hepatocyte (30). This result is in consistent with other studies who reported that cytokine profiles (IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10 and PCT levels were elevated in patients with acute hepatitis, they were concluded that IL-8 is increased in some patients with liver disease, it plays a significant role in host defense and disease (29,31).
This study provides valuable insights into the demographic characteristics, serological profiles, biochemical disturbances, and inflammatory responses in patients with acute hepatitis B.
Recommendations: The findings highlight the need for comprehensive monitoring and management strategies to address the significant liver damage and systemic inflammation associated with acute HBV infection
Jia-Horng K, Ding-Shinn. Hepatitis B Virus and Liver Disease 1st ed. Springer Singapore; 2018:38-91. DOI:10.1007/978-981-10-4843-2
Hasan SF, Maded ZK, Alazzawy MA. Molecular detection of Hepatitis C virus (HCV) genotypes and viral loads in chronic hcv infected patients in Kirkuk, Iraq. Medical Journal of Babylon. 2023 Dec 1;20(Supplement 1): S31-6. DOI: 10.4103/mjbl.mjbl_361_22
Thabit MF, Ali MH, AL-Bahadeli NM. Knowledge about hepatitis B Infection among undergraduate medical and health college students, Baghdad. Mustansiriya M J 2017;16(2):63-7. DOI: 10.3390/ijerph20054348
Sulaiman MM, Salih KN, Raheef NF, Alazzawy MA. Levels of Calcitonin and Procalcitonin in Different Types of Thyroid Cancer in Kirkuk City-Iraq. Indian Journal of Public Health. 2019 Nov;10(11):1959. DOI:10.5958/0976-5506.2019.03936.6
Hughes E, Bassi S, Gilbody S, Bland M, Martin F. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis. Lancet Psychiat 2016;3(1):40-8. doi: 10.1016/S2215-0366(15)00357-0
Al-Azzawy MA. Immunological aspects of ELISA positive PCR negative newly diagnosed hepatitis C patients in Kirkuk province. Al-Kitab Journal for Pure Sciences. 2019;3(2):154-62. DOI:10.32441/kjps.03.02. p13
Molnar MZ, Alhourani HM, Wall BM, et al. Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans. Hepatol 2015;61(5):1495-502. DOI: 10.1002/hep.27664
Saxena R. Practical Hepatic Pathology: A diagnostic approach e-book: A volume in the pattern recognition series. Elsevier Health Sciences; 2017: 212-33. DOI:10.1016/C2009-0-38374-9
Haga Y, Kanda T, Nakamoto S, et al. Interferon induces interleukin 8 and bone marrow stromal cell antigen 2 expression, inhibiting the production of hepatitis B virus surface antigen from human hepatocytes. Biochem Biophysic Res Communicat 2017;486(3):858-63. DOI: 10.1016/j.bbrc.2017.03.150
Chen T, Zhu L, Shi A, et al. Functional restoration of CD56 bright NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B. Hepatol Int 2017;11(5):419-28. doi: 10.1007/s12072-017-9803-4
Mitra S, Leonard WJ. Biology of IL‐2 and its therapeutic modulation: Mechanisms and strategies. J leukocyte Biol 2018;103(4):643-55. https://doi.org/10.1002/JLB.2RI0717-278R
Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, Kamps BS. Hepatology- A Clinical Textbook. 4th ed. Frankfurt: Flying Publisher; 2017:92-300 https://www.hepatologytextbook.com/
Boyer TD, Sanyal AJ, Terrault NA. Hepatology: A Textbook of Liver Disease E-Book. 3rd ed. Elsevier Health Sciences; 2016:162-99. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773747/
Jasim HA. Prevalence and risk factors for hepatitis C and B viruses’ infection among hemodialysis patients in Holy Karbala, Iraq. Kufa J Nurs Sc 2015;5(3):111-6. doi: 10.4103/2277-9175.125869
Mustapha SK, Jibrin YB. The prevalence of hepatitis B surface antigenaemia in patients with human immunodeficiency virus (HIV) infection in Gombe, Nigeria. Gastroenterol Hepatol 2004;171(9):845-60. https://www.semanticscholar.org/paper/THE-PREVALENCE-OF-HEPATITIS-B-SURFACE-ANTIGENAEMIA-Mustapha-Jibrin/37c5321afeb23d16e33a273738a0fb3b2c01a05b
Hama SA, Sawa MI. Prevalence of hepatitis B, C, and D among thalassemia patients in Sulaimani Governorate. Kurdistan J Applied Res 2017;2(2):137-42. doi: 10.1016/j.nmni.2021.100912
Al-Jaaf AM. A study of hepatitis B virus pre-core mutation among Iraqi chronic hepatitis B patients treated with interferon alfa. Council of genetic engineering and biotechnology. Baghdad University. M. Sc. Thesis. 2006. DOI: 10.1128/JVI.01695-20
Youssif TH. Immunological study of patients with chronic active hepatitis B. College of Medicine. Baghdad University. Ph. D. Thesis. 1998. doi: 10.5114/pg.2019.88171
Dolan K, Wirtz AL, Moazen B, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet 2016;388(10049):1089-102. DOI: 10.1016/S0140-6736(16)30769-3
Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol 2016;16(8):509. DOI:10.5812/hepatmon.94377
Seo DH, Whang DH, Song EY, Han KS. Occult hepatitis B virus infection and blood transfusion. World J Hepatol 2015;7(3):600–6. doi: 10.4254/wjh.v7.i3.600
Kwak MS, Kim YJ. Occult hepatitis B virus infection. World J Hepatol 2014;6(12):860-6. doi: 10.4254/wjh.v6.i12.860
Atkinson W, Hamborsky J, Mclntyre I, Wolfe S. Centers for Disease Control and Prevention: Epidemiology and Prevention of Vaccine-Preventable Diseases. 10th ed. Washington DC: Public Health Foundation; 2017: 211-34. https://stacks.cdc.gov/view/cdc/78725
Oluyinka OO, Van Tong H, Tien SB, et al. Occult hepatitis B virus infection in Nigerian blood donors and hepatitis B virus transmission risks. PloS one 2015;10(7):e0131912. doi: 10.1371/journal.pone.0131912
Lavanchy D, Kane M. Global epidemiology of hepatitis B virus infection. In: Hepatitis B Virus in Human Diseases. Humana Press, Cham 2016: 187-03. DOI: 10.1097/00004836-200411003-00008
Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. J Gen Virol 2006; 87:1439-49. DOI:10.1099/vir.0.81920-0
Chwla Y. Hepatitis B Virus: Inactive carriers. J Virol 2005; 28: 82-9. doi: 10.1186/1743-422X-2-82
Attar BM, Moore CM, George M, Ion-Nedelcu N, Turbay R, Zachariah A, Ramadori G, Fareed J, Van Thiel DH. Procalcitonin, and cytokines document a dynamic inflammatory state in non-infected cirrhotic patients with ascites. World Journal of Gastroenterology: WJG. 2014 Mar 3;20(9):2374. doi: 10.3748/wjg.v23.i47.8283
Wang Y, Gu J, Chen G, Jiang Y, Xu Y, Huang X, Gan J. Roles of inflammatory factors in the pathogenesis of hepatitis B virus-related acute-on-chronic liver failure and CAR-T therapy. doi: 10.1016/S0140-6736(20)30183-5
Chalupa P, Beran O, Herwald H, Kaspříková N, Holub M. Evaluation of potential biomarkers for the discrimination of bacterial and viral infections. Infection. 2011 Oct;39:411-7. DOI:10.1007/s15010-011-0126-4
Ribeiro CR, Beghini DG, Lemos AS, Martinelli KG, de Mello VD, de Almeida NA, Lewis‐Ximenez LL, de Paula VS. Cytokines profile in patients with acute and chronic hepatitis B infection. Microbiology and Immunology. 2022 Jan;66(1):31-9. doi: 10.1186/s12985-021-01712-y
Nation, I. S. P. (2001). Learning Vocabulary in Another Language. Cambridge: Cambridge University Press. DOI:10.14198/raei.2002.15.18-2
ELEUTÉRIO, F. P., OLIVEIRA, I. A., SILVA, M. S., & FALEIROS, M. H. V. (2012). Music in the English language classroom: Going beyond the lyrics. Revista Eletrônica de Letras, 4(1). DOI:https://doi.org/10.1039/C3GC37030E